Glenmark Pharma receives ANDA nod for Clindamycin Hydrochloride Capsules

Glenmark Pharma receives ANDA nod for Clindamycin Hydrochloride Capsules

by admin- Tuesday, March 14th, 2023 07:12:46 PM

 

Glenmark Pharmaceuticals received final approval by means of the USA Food & Drug Administration (USFDA) for Clindamycin Hydrochloride Capsules USP, seventy five mg, 150 mg, and 300 mg, the regular version of Cleocin Hydrochloride Capsules, seventy five mg, one hundred fifty mg, and three hundred mg, of Pfizer Inc. Glenmark’s Clindamycin Hydrochloride Capsules USP, 75 mg, a hundred and fifty mg, and 300 mg, could be disbursed in the US via Glenmark Pharmaceuticals Inc., USA.

According to IQVIATM income facts for the 12-month period finishing January 2023, the Cleocin Hydrochloride Capsules, 75 mg, a hundred and fifty mg, and three hundred mg market2 executed annual income of approximately $33.6 million.

 

News Updates